CbsBioscience is the innovative molecular diagnostics company focused on the discovery of novel therapeutic targets and the development and commercialization of the effective CDx technologies for meeting the unmet medical needs in the cancer treatment.
Specializing in the development of companion diagnostics (CDx) and the discovery of anticancer drugs for cancer treatment, CbsBioscience possesses a large amount of multicenter specimens and a clinical information management system regarding the cancer patients, bioinformatic‐based proteomics, genomics technologies, and in-house clinical statistical systems sufficient for high-capacity data processing. Currently, CbsBioscience retains a large number of biomarkers for diagnosis, prognosis, and therapeutic decision and participates in a consortium(KCBC) affiliated with major hospitals in Korea to conduct the clinical experiment efficiently and to develop the anticancer drug. In the future, we will develop the quantitative multi-gene-based CDx technologies and the CDx-based drug for personalized treatment for other cancers including a liver cancer.
CbsBioscience has not received any reviews.
CbsBioscience has not received any endorsements.